Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01712841 · ClinicalTrials.gov registry record

Non-exudative Age-related Macular Degeneration

A clinical trial, sponsored by Oregon Health and Science University.

Completed
Registry status
30
Enrollment target

NCT01712841 is a clinical trial that has completed, run by Oregon Health and Science University. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01712841 has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
30 participants
Enrollment target

Study Summary

Age-related macular degeneration (AMD) is the most prevalent cause of vision loss in developed countries and is often discussed in terms of the "dry" and the "wet" forms. The "wet" form of AMD is the more advanced form of the disease and is responsible for 80% of the legal blindness in AMD. Treatment options include a promising class of biologics called anti-vascular endothelial growth factors, as well as photodynamic therapy and laser surgery. These therapies can slow further vision loss, but cannot achieve recovery of lost vision. The "wet" form of AMD is always preceded by the "dry" form. Therefore, it is reasonable to expect that the early detection and treatment of the "dry" form may help reduce vision loss or progression to the more damaging "wet" form. Unfortunately, symptoms appear only in advanced stages of the "dry" form. As light sensitive cells in the macula breakdown in a process called geographic atrophy, the patient may notice blurred central vision. OCT is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time. It is analogous to ultrasound B-mode imaging, except that OCT measures the intensity of reflected light rather than acoustical waves. This study aims is to use OCT technology to compare how the retinal anatomy and blood flow differ within three severity groupings of non-exudative age-related macular degeneration (NEAMD).

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2012-10
Est. Completion 2018-01-18

What the Registry Record Tells You About NCT01712841

The ClinicalTrials.gov registry entry for NCT01712841 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01712841 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01712841 about?

NCT01712841 is a clinical study titled "Non-exudative Age-related Macular Degeneration". Age-related macular degeneration (AMD) is the most prevalent cause of vision loss in developed countries and is often discussed in terms of the "dry" and the "wet" forms. The "wet" form of AMD is the more advanced form of the disease and is responsible for 80% of the legal blindness in AMD. Treatmen...

What is the current status of trial NCT01712841?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2012-10. Estimated completion is 2018-01-18.

Who is sponsoring clinical trial NCT01712841?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.